Growing CRO, Venn Life Sciences, has announced its acquisition of French CRO Cardinal Systems SAS in a deal worth at least €600,000.
The acquisition extends Venn’s service offering into Data Management and Randomisation, a customer requirement that was previously outsourced, and so further strengthens the Company’s position as a leading full-service European CRO.
Tony Richardson, CEO of Venn Life Sciences, said: “The combination of Cardinal’s IT expertise with Venn’s extensive clinical trial management experience enables us to offer our sponsors a more holistic approach to managing their trials. This enhances our growth opportunities as a company as we can target a wider portfolio of studies and we have already encountered positive feedback from potential customers in anticipation of this kind of deal.”
The Cardinal team will continue to be based out of the Paris office and will work in tandem with each of the Venn offices across Europe.